Stemline Therapeutics Offers Top-Line Results from Lead-In Stage of Ongoing BPDCN Pivotal Trial: Says SL-401 Showed Multi-Cycle Safety, Efficacy

By: via Benzinga
Stemline Therapeutics, Inc. (Nasdaq: STML) today announced top-line results from the lead-in stage of its ongoing SL-401 pivotal trial ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.